The Medicare hospice benefit, authorized in 1982 under part A of the Medicare program, covers medical and palliative care services for terminally ill beneficiaries. A Medicare-certified hospice provides physician services, nursing care, physical and occupational therapy, home health aide services, medical supplies and equipment, and short-term inpatient hospital care for pain control and symptom management. In addition, the hospice benefit provides coverage for several services not generally available under the regular fee-for-service Medicare benefit. These include outpatient prescription drugs for treating pain and other symptoms of the terminal illness, homemaker services, short-term inpatient respite care, and bereavement counseling for the patient’s family. Patients may receive services from freestanding hospice providers or from a hospice program based in a home health agency, hospital, or skilled nursing facility. For each day a beneficiary is enrolled, the hospice provider is paid an all-inclusive, prospectively determined rate, depending on the level of hospice care provided (routine home care, continuous home care, inpatient respite, or general inpatient care).Initial payment rates were based on cost data reported by 26 hospice programs that participated in Medicare’s hospice demonstration project from 1980 to 1982.Since 1993, these rates have been updated by an annual statutory adjustment factor tied to inflation in the hospital market basket (a measure of the cost of goods and services purchased by hospitals nationwide). Eligibility for hospice services requires that the beneficiary’s physician and the hospice medical director (or other physician affiliated with the hospice) certify that the individual’s prognosis is for a life expectancy of 6 months or less, if the terminal illness runs its normal course. Beneficiaries who elect hospice must waive all other Medicare coverage of care related to their terminal illness, although they retain coverage for services unrelated to their terminal illness. A beneficiary can cancel his or her election of hospice benefits at any time and return to regular Medicare, and beneficiaries are free to reselect hospice coverage at a later date. While there are currently no limits on the number of days an individual can receive hospice care, a beneficiary’s prognosis must be reaffirmed at 90 days, at 180 days, and every 60 days thereafter. The hospice eligibility requirement that a beneficiary be certified as having a prognosis of 6 months or less has been an ongoing concern expressed by advocates and providers. The requirement has been challenged as difficult to implement and a deterrent to hospice referrals, especially for beneficiaries with noncancer diagnoses. Research suggests that it can be difficult for physicians to accurately predict whether a patient is likely to die within 6 months.It is particularly difficult to estimate life expectancy for persons with noncancer diagnoses because the course of their disease is likely to be erratic.For example, patients with heart disease are more likely to die suddenly than persons with cancer, who commonly have a period of steady decline before death. Similarly, very elderly people in frail health or with certain chronic illnesses may experience long periods of declining health punctuated by several medical crises—any one of which can be fatal. In such cases, physicians may find it difficult to justify a hospice referral for beneficiaries who appear to be relatively stable, and, as a result, the physicians may delay initiation of hospice services until a medical crisis occurs shortly before death. From 1992 to 1998, the number of Medicare beneficiaries enrolling in hospice more than doubled, with growth in all population subgroups and in all states. Growth was particularly rapid among beneficiaries with diagnoses other than cancer. At the same time, many beneficiaries had shorter stays. On average, the days of hospice service used per beneficiary declined by about one-fifth during the 7-year period and beneficiaries with diagnoses other than cancer experienced the sharpest reductions. Our analysis of Medicare claims data indicates substantial growth in hospice use. The number of beneficiaries electing hospice care increased 2 ½ times from 1992 to 1998, from about 143,000 to nearly 360,000 persons annually. (See fig. 1.) Across most demographic groups, the use of hospice services has grown at a relatively consistent rate. Thus, hospice users today are similar to users in 1992; the distribution of enrollees by race has not changed (89 percent are white), and the proportion of enrollees who are women has climbed only slightly (from 50 to 54 percent). However, the use of hospice services grew more rapidly among beneficiaries aged 80 and older than it did among younger beneficiaries. This age group now makes up 47 percent of Medicare hospice enrollees, up from 35 percent in 1992. Overall, 19 percent of Medicare beneficiaries who died in 1998 received hospice services, compared with 8 percent in 1992.However, this measure understates the proportion of Medicare beneficiaries who choose hospice care among those for whom the benefit was intended. According to a former president of the National Hospice Organization, “when the number of deaths nationwide is adjusted to reflect only those that are likely to be appropriate for hospice care, the percentage of dying patients cared for in hospice care is probably about 40 percent.” Some groups of beneficiaries are more likely to choose hospice services than others. For example, 20 percent of white Medicare beneficiaries who died in 1998 elected hospice services, compared with 15 percent of black beneficiaries who died that year. Similarly, the use of hospice services is more common among beneficiaries who are enrolled in Medicare health maintenance organizations (HMO) at the end of life than among those in fee-for-service plans. Of the beneficiaries who died in 1998, 27 percent of those enrolled in an HMO elected hospice, compared with 18 percent of fee-for-service beneficiaries.(See app. II for detailed information about hospice use rates among decedents.) In addition, the proportion of Medicare decedents who used the hospice benefit varies widely by state. For example, in 1998, the number of hospice users as a share of Medicare decedents was more than four times higher in Arizona than in Maine. Table 1 shows states with the highest and lowest rates of hospice use in 1998. Although people who die from cancer are more likely to choose hospice services than are those who die from other conditions, the use of hospice services by beneficiaries with noncancer diagnoses has increased rapidly. From 1992 to 1998, hospice enrollment by beneficiaries with cancer increased 91 percent, while enrollment by beneficiaries with all other conditions increased 338 percent. The most dramatic growth in use was among individuals with other terminal conditions, such as heart disease, lung disease, stroke, or Alzheimer’s disease. About 43 percent of beneficiaries who elected hospice in 1998 had noncancer diagnoses, compared with about 24 percent in 1992. Table 2 shows the distribution of new hospice enrollees by primary diagnosis. For many of the leading causes of death, the proportion of elderly decedents who use the hospice benefit has increased. In 1997, about half of the people aged 65 and older who died from cancer had used hospice services, compared with about one-fourth in 1992.This pattern generally held for breast cancer, lung cancer, and prostate cancer. However, the use of hospice services is even more common among persons with other types of cancer; roughly 75 percent of people age 65 and older who died from brain or liver cancer in 1997 used hospice services before death. The proportion of elderly decedents who used hospice services also increased among beneficiaries who died from other causes. Table 3 shows the change in hospice use rates from 1992 to 1997 for common hospice diagnoses. Although more Medicare beneficiaries are receiving hospice services, on average, they are receiving fewer days of care than did beneficiaries in the past.From 1992 to 1998, average length of stay declined 20 percent (from 74 to 59 days), while median length of stay declined 27 percent (from 26 to 19 days).(See fig. 2.) The overall decline in average length of service appears to have been driven by both (1) a reduction in the proportion of beneficiaries with very long hospice stays and (2) an increase in the share of users with very short stays.(See table 4.) From 1992 to 1998, the share of hospice enrollees with more than 6 months of service use declined from 9.3 to 7.3 percent. Over the same period, the proportion of beneficiaries who used hospice for a very brief period before death rose sharply. In 1998, 28 percent of all beneficiaries using hospice care did so for 1 week or less. The decline in the average number of hospice days used has been especially dramatic among beneficiaries with a primary diagnosis other than cancer. While these beneficiaries historically had many more days of care than cancer patients, the average number of days used declined 38 percent between 1992 and 1998. In comparison, average days used by beneficiaries diagnosed with cancer declined by 14 percent. As a result, differences in length of stay across diagnosis categories have narrowed considerably. In 1998, cancer patients used an average of 54 days while noncancer patients used 68 days, on average. Figure 3 compares the decline in the average number of hospice days used for beneficiaries with cancer and noncancer diagnoses. At the state level, average length of service declined in 42 of 50 states and the District of Columbia from 1992 to 1998, and variation in average length of service across states lessened considerably. (State data appear in app. II.) In 1992, 27 states had average service periods within 10 days of the 74- day national average. By 1998, 36 states had average service periods within 10 days of the 59-day average. Several factors influence beneficiary choice about whether and when to use hospice care. These include physician preferences and referral practices, individual patient choice and circumstances, and general awareness of the benefit among the public and professional communities. In addition, recent federal oversight of compliance with patient eligibility requirements may have affected certain beneficiaries’ use of the hospice benefit. Although Medicare beneficiaries and their families make the decision about whether and when to initiate hospice services, physician willingness to discuss options for end-of-life care is important to the decision. However, the research literature indicates that not all physicians are comfortable discussing end-of-life care, and some may hesitate to suggest hospice care for other reasons, such as concerns about relinquishing control of their patients’ care. Even when the issue has been broached, some beneficiaries choose instead to continue curative or life-extending treatments. Patient advocacy groups, several medical societies, and others have called for greater public and professional awareness of options for care of the dying, which has led to a range of educational efforts designed to increase awareness of hospice and its benefits. The research literature indicates that because patients and their families rely heavily on physician recommendations for treatment, including recommendations for end-of-life care, physicians are an influential factor in patient entry into hospice. Physicians initiate most referrals to hospice, and they may continue to care for their patients after enrollment as part of the hospice team. However, research has shown that many physicians are poorly trained in the care of the dying and are often uncomfortable discussing options for end-of-life care or the cessation of curative treatment.A recent review of 50 top-selling textbooks from several medical specialties found that most provided inadequate information on end-of-life issues, with oncology textbooks among those particularly likely to provide no information about key aspects of end-of-life care.Physician referral to hospice may be limited by other factors, as well. For example, experts in the area of palliative care, as well as the research literature, suggest that some physicians may not be aware that they can continue to provide services after a beneficiary has entered hospice and may delay referral out of concern about losing control of the patient’s care. The use of hospice services by Medicare beneficiaries requires not just awareness of the benefit and a physician’s certification of prognosis but also acceptance that death is the outcome of their illness and the choice by beneficiaries to give up a portion of their standard Medicare benefits in order to receive hospice care. Once enrolled, no other services related to a patient’s terminal condition are covered under Medicare. HCFA officials and others also noted that improvements in cancer care and the addition of new treatment options may be prompting some beneficiaries to pursue new curative options until very shortly before death, thus contributing to the trend of shorter hospice stays. Other beneficiaries may favor continuing aggressive, life-extending treatments up until the time of death and not enter hospice at all. According to HCFA officials, it may be that some terminal patients do not want hospice care, and that should be their right. Research suggests that beneficiaries who do not consider hospice care may be unwilling to confront the terminal nature of their illness, may not know that the alternative exists, or may misunderstand the services available through hospice care. The Institute of Medicine (IOM) noted that patients are influenced by the general unwillingness to accept limits of all types, including those of aging and death.A Gallup poll in 1996 found that although a majority of people expressed interest in hospice care, most also said that they would still seek curative care. In some cases, a beneficiary’s circumstances may complicate hospice enrollment. Hospice is designed to allow the beneficiary to remain at home during his or her last few weeks of life, where family and friends are expected to deliver most of the routine day-to-day care. Hospice staff offer more specialized care and respite care to give family members a break when they need one. Thus, some hospice programs limit participation to beneficiaries who have a caregiver at home. Others permit such beneficiaries to enter the hospice program with the understanding that transfer to a nursing home will be required when their needs for assistance reach a certain stage. Public and professional awareness also influences the use of the Medicare hospice benefit. The need for greater public and professional understanding of options for end-of-life care, including hospice, has been highlighted in several recent congressional hearings and in other public forums.In addition, several medical societies, patient advocacy groups, and the hospice industry have undertaken a variety of efforts to educate their members and the public about end-of-life care options. For example, the American Medical Association and the Robert Wood Johnson Foundation are developing a core curriculum for educating physicians in end-of-life care. The Medicare Rights Center, a consumer advocacy and education organization, is conducting a national campaign to increase awareness of the Medicare hospice benefit among health professionals. Also, the National Hospice and Palliative Care Organization has published a variety of materials on public education and outreach strategies for its members. Industry and patient advocacy groups contend that recent federal scrutiny of provider compliance with program eligibility requirements has inappropriately limited access to hospice for certain beneficiaries. While federal scrutiny may have contributed somewhat to the existing trend toward shorter hospice enrollment periods, continued growth in the number of beneficiaries receiving hospice services makes it difficult to identify the extent to which federal scrutiny may have deterred access. Furthermore, the use of hospice services has increased most rapidly among beneficiaries with diagnoses other than cancer—those for whom arriving at a 6-month prognosis may be more difficult. In 1995 and 1996, the Department of Health and Human Services’ (HHS) Office of the Inspector General (OIG) investigated the eligibility status of Medicare beneficiaries receiving hospice services as part of a larger investigation of fraud and abuse in Medicare. Specifically, OIG reviewed the admission decisions made for hospice patients with very long stays at 12 hospices in four states; it found that many of these patients did not meet eligibility criteria upon admission to hospice. OIG followed this effort with other reviews of beneficiary eligibility, encompassing a larger sample of hospices, and found that the vast majority of Medicare beneficiaries receiving hospice services were eligible for such services. Patient advocacy groups and the hospice industry assert that this federal scrutiny of compliance with the 6-month eligibility rule has had a chilling effect on entry into hospice for noncancer beneficiaries, for whom it may be more difficult to establish a 6-month prognosis with confidence. They contend that hospice providers are more cautious about admitting beneficiaries with noncancer diagnoses as a result, leading to delays in hospice entry for persons wishing to use the benefit. Although the percentage increase in beneficiaries electing hospice slowed somewhat from 1995 through 1998 compared with the prior period, it is difficult to know what portion of this slower growth is attributable to the effect of federal scrutiny and what portion is attributable to other factors, such as the larger base of beneficiaries already using hospice. The OIG scrutiny of beneficiary eligibility may have contributed to later hospice entry for some beneficiaries, to the extent that hospice providers responded to the oversight with greater caution about beneficiary eligibility. However, the trend toward fewer days of hospice use began before the period of federal scrutiny. As shown in figure 4, the average length of service for both cancer and noncancer hospice users peaked by 1994, before scrutiny of the hospice benefit increased. Furthermore, physician groups we spoke with did not cite caution among hospice providers about beneficiary eligibility as a primary barrier to the initiation of hospice services for their patients. According to the American Society of Clinical Oncology, barriers to timely hospice care for cancer patients include the attitudes of physicians and patients toward death and reluctance to talk about death until the very end of life. While the OIG reviews were under way, the National Hospice Organization developed guidelines to assist physicians and hospices in determining a 6- month prognosis for patients with selected noncancer diagnoses. These included amyotrophic lateral sclerosis (ALS), dementia, human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), heart disease, pulmonary disease, liver disease, stroke and coma, and kidney disease. In order to enhance accuracy and uniformity in the claims review process, HCFA distributed these guidelines to the intermediaries that process hospice claims for Medicare to use in assessing compliance with benefit requirements.The intermediaries have since adopted these guidelines as formal local medical review policies. Concerns have been raised that using these guidelines as a standardized basis for determining Medicare hospice eligibility limits access to hospice, particularly for patients with noncancer diagnoses. Industry representatives assert that the guidelines require further development to improve prognostic confidence and accuracy before they would be appropriate as formal medical review policies. However, intermediaries point out that while medical review policies specify clinical criteria for establishing a patient’s 6-month prognosis, they allow for variation in individual cases. For example, one intermediary’s medical review policy for heart disease notes that “some patients may not meet the criteria, yet still be appropriate for hospice care, because of other comorbidities or rapid decline.” According to Medicare program guidance to all hospices, the fact that a hospice patient lives beyond 6 months does not, by itself, constitute grounds for a determination that the patient was never eligible for hospice care or that Medicare does not cover services provided to the patient. Typically, if a question is raised as to whether a patient is terminally ill, the intermediary asks the hospice to furnish information necessary to affirm the patient’s prognosis. The rates of medical reviews of claims began increasing in 1995, at HCFA’s direction.Four of the five intermediaries reported that, by 1999, review rates ranged from 0.8 to 4.2 percent of all hospice claims processed. Nearly all the hospice providers we spoke with said they consult their intermediaries’ medical review policies as part of the admission screening process. Asked about the effect of the review policies on admitting patients, some hospices reported that using these criteria has decreased the likelihood of admitting patients with noncancer conditions, while others said that the review criteria have increased the likelihood of admissions or have had no effect at all. Sustained growth in the number of hospice providers participating in Medicare and in their distribution throughout the country suggests that hospice services are now more widely available to program beneficiaries. While all sectors of the hospice industry have grown over the past decade, recent growth has been particularly strong in the for-profit sector and among large hospice programs. At the same time, hospice industry officials report growing cost pressures from shorter patient stays and changes in the practice of palliative care. Because data on provider costs are not available, however, it is not clear how these cost factors affect providers and beneficiaries. Although the overall rate of growth has slowed somewhat in the past few years, new hospice providers continue to enter the Medicare program every year. As shown in figure 5, the number of Medicare-certified hospice providers nationwide grew by 82 percent from 1,208 in 1992 to 2,196 in 1999.Each year during the period, additional hospice programs became certified for Medicare, although the number of new entrants declined from 274 in 1994 to 46 in 1999, and the number of hospices leaving Medicare exceeded the number of new entrants in 1999. (Many of those leaving were based in home health agencies (HHA) that may have closed because of changes in HHA payments enacted in BBA.) The increased number reflects not only new hospices but also growing participation in Medicare. (See app. II for more detail on changes in hospice supply and distribution.) In 1989, we estimated that only about 35 percent of the approximately 1,700 hospice providers nationwide participated in Medicare. By 1998, the National Hospice and Palliative Care Organization estimated that 80 percent of hospices were certified to serve Medicare patients. Over this period, all types of hospice providers grew, in rural and urban areas and in almost every state. From 1992 to 1999, the rate of growth was greatest among for-profit providers and those in rural areas. Also, large providers accounted for an increasing share of the services delivered. (See table 5.) The number of for-profit providers increased nearly fourfold, and the number of large hospice programs (those serving 500 or more Medicare patients per year) more than tripled over the period.In addition, the number of rural providers increased by 116 percent while the number of urban-based providers increased 64 percent. Even with high growth in these sectors of the industry, the majority of hospices are small programs (with fewer than 100 Medicare patients per year), organized as not-for- profit, and located in urban areas. Even with certificate-of-need (CON) requirements that apply to hospice providers in 14 states, the number and size of Medicare hospice providers increased in almost every state from 1992 to 1998.Among states with large Medicare enrollment and no CON requirements, the most dramatic growth was in Texas, where the supply of hospice providers relative to the size of the Medicare population nearly doubled. Among the CON states with large Medicare populations, providers increased the number of patients served, while growth in the number of providers was constrained. For example, in Florida and New York the number of hospices per million beneficiaries remained virtually unchanged; however, the number of beneficiaries each hospice served grew 66 and 105 percent, respectively. (See table 6.) Even as the hospice industry has grown, changes in the use of the hospice benefit and the delivery of hospice care have raised concerns about cost among providers. Most significantly, declines in the average enrollment period have resulted in fewer days over which providers can spread the fixed costs associated with a patient’s stay in hospice. In addition, providers report that changes in the practice of palliative medicine have made the use of higher-cost services more common. However, because reliable data on provider costs are not available, it is not clear how these factors may effect hospices’ financial status or their ability to serve Medicare beneficiaries. Industry representatives point out several areas of change that they contend are adversely affecting the financial condition of providers. Specifically, Under Medicare’s per diem payment system for hospice care, hospices have traditionally offset the higher-cost days that occur at admission and during the period immediately preceding death with lower-cost days of less intensive care.For example, costs for admitting and assessing a new patient, establishing a care plan, and delivering medical equipment are incurred during the first few days of enrollment and do not vary with the patient’s period of service. As enrollment periods have declined, hospices have had fewer days over which they can spread the higher costs associated with the start and end of a patient’s stay. As more patients enter hospice later in the course of their terminal illness, they enter with higher levels of impairment and in need of more intensive services. In addition, the shift in the mix of patients by diagnosis may have increased the average service needs for the overall hospice population. According to the most recent National Home and Hospice Care Survey, hospice patients with noncancer diagnoses are somewhat more likely than those with cancer to be functionally impaired and thus may require more services on a regular basis from hospice agencies. Physicians and patients are calling on hospice programs to provide a broader array of palliative services than in the past. Costly treatments such as chemotherapy and radiation—traditionally used for curative purposes—are increasingly used in the hospice setting to manage pain and other symptoms. Furthermore, some new palliative care treatment options, such as the transdermal administration of narcotic pain medication, may offer better symptom control for some patients but often at greater expense. To the extent that hospice providers believe that Medicare payments do not adequately cover their costs, they may have an incentive to limit their acceptance of patients who need more intensive services or limit the types and amount of services they make available.Providers may also respond by choosing not to admit patients who are expected to be more expensive. However, hospice officials we interviewed reported being able to enroll most patients who were referred. With the exception of patients lacking sufficient informal caregiver support, the potential cost of care and payment rates were not generally cited as factors limiting the admission of eligible patients. Data to assess how declining patient stays and changes in palliative care practices affect overall provider costs are not currently available. While certain more expensive services may be provided more frequently, the share of total costs that these services currently represent is unknown.Furthermore, we do not know the extent to which providing more expensive medications or treatments to hospice patients may reduce the need for other services such as nursing visits. In response to BBA requirements, HCFA has begun collecting hospice cost data to use in evaluating the adequacy of current levels of Medicare reimbursement. Officials anticipate that audited hospice cost data will be available beginning in late 2001. Trends in the use of the Medicare hospice benefit during the 1990s indicate that beneficiaries with all types of terminal illnesses are making use of hospice services in greater numbers every year. In particular, the types of patients selecting hospice have expanded broadly—from mostly beneficiaries with cancer to a nearly even split among those with cancer and those with other terminal conditions. In spite of these trends in use, and the widespread availability of hospice providers, patient advocates and the industry are concerned about the trend toward using fewer days of hospice care. Because many factors influence the use of hospice care, and potential demand is difficult to determine, the extent to which the Medicare hospice benefit may be underutilized is not clear. We provided a draft of this report to HCFA for review. In its comments, HCFA discussed the importance of the hospice benefit to the Medicare program and efforts to ensure that beneficiaries, physicians, and hospice providers understand the benefits’ coverage and eligibility criteria. Furthermore, HCFA stated that it does not believe the underutilization concerns of hospice advocates and the industry should be discounted. It noted that enrollment in hospice may not be an option for beneficiaries who lack family support at home or that it may be delayed for patients who wish to continue curative care treatments. HCFA’s comments appear in appendix III. The agency made technical comments that we incorporated where appropriate. As we agreed with your office, unless you publicly announce the report’s contents earlier, we plan no further distribution of it until 30 days after the date of this letter. We will then send copies to the Honorable Donna Shalala, Secretary of HHS; the Honorable Min DeParle, Administrator of HCFA; and others who are interested. We will also make copies available to others on request. If you or your staff have any questions, please call me at 202-512-7119 or Rosamond Katz, Assistant Director, at 202-512-7148. Other major contributors were Eric Anderson, Jenny Grover, Wayne Turowski, and Ann White. Our study is an analysis of national hospice enrollment, use patterns, and industry developments from 1992 through 1998. We examined Medicare beneficiary claims data for hospice services to determine hospice use rates for different groups of beneficiaries. We also gathered descriptive information about the hospices that provided the services. We used the Medicare Hospice Standard Analytic File of the Health Care Financing Administration (HCFA) to identify beneficiaries who enrolled in hospice during the study period and to determine their pattern of hospice use. To conduct an analysis of hospice enrollment by year, we assigned beneficiaries to the year of their first hospice claim. We excluded beneficiaries from our analysis if total payment for a beneficiary was less than $75 or was $1 million or more, if a beneficiary at the time of a first hospice claim was younger than 20 or older than 110, or if a beneficiary’s residence was not in one of the 50 states or the District of Columbia. Our analysis of beneficiary use includes information on age at the time of entry into hospice (younger than 65, 65 to 74, 75 to 84, 85 and older), gender, race and ethnicity (white, black, Hispanic, and other), state of residence, enrollment in managed care or fee-for-service Medicare (based on status in the month of death, from the HCFA denominator file), and primary diagnosis (three-digit International Classification of Disease code). Analysis of the beneficiary claims data showed that 98 percent of beneficiaries had only one hospice provider, and 97 percent had only one diagnosis code. Therefore, we conducted all further analysis on the basis of the provider and diagnosis listed in the first hospice claim for each beneficiary. We calculated the period of enrollment by summing the number of days covered by each claim, even if they covered discontinuous periods of service, and excluded duplicate claims.Because records of hospice use are not complete for beneficiaries who entered hospice during the later years of our study period, we adjusted the claimed days of hospice service for 1996 to 1998 to better account for beneficiaries with very long stays.Our adjustment factor was calculated from 1992-95 data on the proportion of total beneficiary claim days accounted for within the first 2 calendar years of hospice use. We also described hospice use rates among different groups of Medicare decedents. To calculate the rate of hospice use, we identified the number of Medicare decedents each calendar year who had used hospice before death. We used the HCFA Denominator File to identify all Medicare decedents belonging to each demographic group in our analysis.Because the HCFA Denominator File does not contain information about beneficiary diagnosis, we used Centers for Disease Control and Prevention (CDC) mortality data to determine the number of deaths among people aged 65 and older. We used annual Medicare Provider of Service Files to identify hospice characteristics. These files contain data on provider certification and status, such as facility and service characteristics, provider type, and location. We included hospices that received total Medicare payments of $75 or more during our study period. The provider identification number from the first hospice claim for each beneficiary was matched with the Provider of Service file data available for that provider. We characterized providers by type of control (profit, not-for-profit, or government), affiliation (freestanding, hospital-based, home health agency, and skilled state, urban or rural location, and number of Medicare beneficiaries receiving services from each hospice each year (small defined as fewer than 100 beneficiaries, medium defined as 100 to 499 beneficiaries, and large defined as 500 or more beneficiaries). The first copy of each GAO report is free. Additional copies of reports are $2 each. A check or money order should be made out to the Superintendent of Documents. VISA and MasterCard credit cards are accepted, also. Orders for 100 or more copies to be mailed to a single address are discounted 25 percent. Ordersbymail: U.S. General Accounting Office P.O. Box 37050 Washington, DC 20013 Ordersbyvisiting: Room 1100 700 4th St. NW (corner of 4th and G Sts. NW) U.S. General Accounting Office Washington, DC Ordersbyphone: (202) 512-6000 fax: (202) 512-6061 TDD (202) 512-2537 Each day, GAO issues a list of newly available reports and testimony. To receive facsimile copies of the daily list or any list from the past 30 days, please call (202) 512-6000 using a touchtone phone. A recorded menu will provide information on how to obtain these lists. Web site: http://www.gao.gov/fraudnet/fraudnet.htm e-mail: fraudnet@gao.gov 1-800-424-5454 (automated answering system)

Summary: Pursuant to a congressional request, GAO provided information on the Medicare hospice benefit, focusing on: (1) the patterns and trends in hospice use by Medicare beneficiaries; (2) factors that affect the use of the hospice benefit; and (3) the availability of hospice providers to serve the needs of Medicare beneficiaries. GAO noted that: (1) the number of Medicare beneficiaries choosing hospice services has increased substantially; (2) in 1998, nearly 360,000 Medicare beneficiaries enrolled in a hospice program, more than twice the number who elected hospice in 1992; (3) of Medicare beneficiaries who died in 1998, about one in five used the hospice benefit, but use varies considerably across the states; (4) although cancer patients account for more than half of Medicare hospice patients, growth in use has been particularly strong among individuals with other common diagnoses such as heart disease, lung disease, stroke, and Alzheimer's disease; (5) although more beneficiaries are choosing hospice, many are doing so closer to the time of death; (6) the average period of hospice use declined from 74 days in 1992 to 59 days in 1998; (7) half of Medicare hospice users now receive care for 19 or fewer days, and care for 1 week or less is common; (8) many factors influence the use of the Medicare hospice benefit; (9) decisions about whether and when to use hospice depend on physician preferences and practices, patient choice and circumstances, and public and professional awareness of the benefit; (10) along with these factors, increases in federal scrutiny of compliance with program eligibility requirements may have contributed to a decline in the average number of days of hospice care that beneficiaries use; (11) the growth in the number of Medicare hospice providers in both urban and rural areas and in almost every state suggests that hospice services are more widely available to program beneficiaries than in the past; (12) between 1992 and 1999, the number of hospices participating in Medicare increased 82 percent, with large providers and those in the for-profit sector accounting for a greater proportion of the services delivered; (13) at the same time, hospice industry officials report cost pressures from declining patient enrollment periods and increased use of more expensive forms of palliative care; (14) because reliable data on provider costs are not available, however, the effect of these reported cost pressures on the overall financial condition of hospice providers is uncertain; and (15) as required by the Balanced Budget Act of 1997, the Health Care Financing Administration began collecting information in 1999 from hospice providers about their costs to allow a reevaluation of the Medicare hospice payment rate.